Derivation Web

source_0ad95ddd5d154ffd

by researka:v2 · 2026-06-22 18:16:56.244262+04:00

# Hypothesis-Generating Brief: GLP-1 longevity — full paper
## Abstract

Evidence-honesty note: 27/52 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 50/52 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Glucagon-like peptide-1 (GLP-1) receptor agonists produce substantial cardiometabolic and weight effects, but whether these translate into a longevity advantage — a central question in the GLP-1 debate — remains contested because no trial is powered for hard aging endpoints.

We conducted an AI-assisted structured evidence synthesis with a per-claim audit trail, in which each cited finding is linked to a source and an outcome class; we did not invoke preclinical or surrogate evidence to substitute for direct human longevity data, following the methodological caution of Ioannidis 2005 that surrogate endpoint associations do not guarantee hard-outcome validity.

Body-composition signals are no less ambiguous, because the canonical sarcopenia grip-strength cutoffs of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019) and the WHO 2000 obesity threshold of 30 kg/m2 are the very benchmarks the GLP-1 claim must respect, and Effect of Oral Semaglutide 2026 and Ghanim 2024 provide only direct or null evidence on lean mass preservation, not longevity per se.

Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

## Introduction

This synthesis evaluates evidence on GLP-1 longevity across 52 included source papers and 1577 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, indirect interventional hard-endpoint evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 2 direct clinical sources, 50 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The thesis is: Across 52 curated reference papers, the evidence base for Glp 1 shows a context-dependent profile. Positive signals appear in: longevity, mortality survival. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Glp 1 anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

## Background

Geroscience frames aging as a unitary biological process in which a discrete set of hallmark mechanisms — mitochondrial dysfunction, cellular senescence, deregulated nutrient sensing, stem-cell exhaustion, altered intercellular communication, and others — can be targeted to delay or compress morbidity and extend healthspan (canonical threshold anchors include Studenski 2011's 0.8 m/s gait-speed marker and Cruz-Jentoft 2019's 27 kg / 16 kg grip-strength cutoffs). This framework has regulatory implications: if aging itself is repositioned as a treatable condition, the field requires outcome measures that are sensitive to the tempo of functional decline and not solely to discrete disease events, a methodological caution reinforced by Ioannidis 2005 on surrogate endpoints. The present synthesis is anchored in GLP-1 — the proposal that glucagon-like peptide-1 receptor agonism, alone or combined with dual incretins, may shift trajectories on these aging-relevant endpoints. Across 52 curated references, however, the GLP-1 case is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and boundary conditions remain to be established.

The preclinical and disease-model profile of incretin drugs, including dual and triple agonists, supplies the mechanistic plausibility for the Glp 1 hypothesis. Incretin pathways couple nutrient sensing to downstream cellular energetics, inflammation, and stress responses, intersecting several hallmarks central to geroscience (Mullur 2024). The corpus further suggests that pleiotropic actions on incretin drug signaling extend beyond glycemic control, with documented or hypothesized effects on blood pressure, lipid handling, and inflammatory tone (Zietek 2016; Rivera 2024). The receptor pharmacology underlying Glp 1 candidacy includes long-acting GLP-1 receptor agonists such as semaglutide, with structural homology to endogenous GLP-1 and extended half-life, and the dual GIP/GLP-1 receptor agonist tirzepatide (Alkhatib 2025; Schneck 2024). Nonetheless, the same corpus surfaces heterogeneity: observational and review-level evidence documents both favorable and null effects on intermediate cardiometabolic surrogates, suggesting that incretin drug mechanisms do not translate uniformly across all populations or comorbidity profiles.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-glp_1_longevity-v06-DAILY-2026-06-22T12-31-32Z-R2`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-22.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `GLP-1 receptor agonist AND aging AND human`
- `semaglutide AND longevity AND healthspan`
- `tirzepatide AND cardiovascular outcomes AND trial`
- `GLP-1 AND inflammation AND older adults`
- `semaglutide AND lean mass AND sarcopenia`

### Eligibility criteria
- Sources whose primary content addresses glp 1 longevity.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 391 records in the receipt-candidate union, 80 were classified as source candidates and 52 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| Receipt candidate union | 391 |
| Classified source candidates | 80 |
| No extractable claims | 104 |
| None-only claim binding | 14 |
| Mixed partial-or-none claim-binding candidates | 79 |
| Partial-only claim-binding candidates | 84 |
| Strict high-confidence sources | 30 |
| Admitted final sources | 52 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune and inflammation, longevity, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Results
| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Cardiometabolic | n=18; claims=547 | no extracted directional signal in 9/18 sources | 1 direct; 12 indirect; 5 review | limited corpus depth in this outcome class |
| Contextual Adjacent Evidence | n=16; claims=563 | no extracted directional signal in 10/16 sources | 9 indirect; 7 review | limited corpus depth in this outcome class |
| Longevity | n=7; claims=234 | unclear signal in 3/7 sources | 3 indirect; 4 review | limited corpus depth in this outcome class |
| Safety and Comorbidity | n=4; claims=87 | no extracted directional signal in 3/4 sources | 3 indirect; 1 review | limited corpus depth in this outcome class |
| Mortality and Survival | n=2; claims=92 | positive signal in 1/2 sources | 1 indirect; 1 review | limited corpus depth in this outcome class |
| Muscle Function | n=2; claims=2 | unclear signal in 2/2 sources | 1 direct; 1 review | limited corpus depth in this outcome class |
| Deficiency Prevalence | n=1; claims=7 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |
| Dosing and Pharmacokinetics | n=1; claims=44 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |
| Immune and Inflammation | n=1; claims=1 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |





**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.



### Results Summary

- Cardiometabolic: n=18; claims=547; no extracted directional signal in 9/18 sources | directness: 1 direct; 12 indirect; 5 review; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=16; claims=563; no extracted directional signal in 10/16 sources | directness: 9 indirect; 7 review; main limitation: no direct clinical anchor.
- Longevity: n=7; claims=234; mixed signal in 3/7 sources | directness: 3 indirect; 4 review; main limitation: no direct clinical anchor.
- Safety and Comorbidity: n=4; claims=87; no extracted directional signal in 3/4 sources | directness: 3 indirect; 1 review; main limitation: no direct clinical anchor.
- Mortality and Survival: n=2; claims=92; benefit signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.
- Muscle Function: n=2; claims=2; mixed signal in 2/2 sources | directness: 1 direct; 1 review; main limitation: population and endpoint heterogeneity.

### Cardiometabolic Outcomes


The cardiometabolic outcome class is the most heavily populated in the corpus, with seventeen source entries spanning randomized trials, observational cohorts, systematic reviews, and case reports in populations ranging from adults with type 2 diabetes to adolescents with obesity.

The quantitative spread within the cardiometabolic literature is wide.

Mechanistically, the cardiometabolic evidence in this corpus maps onto canonical GLP-1 receptor pathways including glycemic lowering, weight reduction, blood pressure decrement, and lipid modulation, which are most cleanly read in clinical RCT material such as Impact of GLP Receptor 2026 and in meta-analytic synthesis such as Rivera 2024. Crowley's case report (Crowley 2024) on lymphedema and Hashimoto 2025 on combined obesity-diabetes management extend the mechanistic substrate into adjacent cardiometabolic territory, while Fang 2026 reviews the dual GIP/GLP-1 agonist tirzepatide in obstructive sleep apnea as a downstream BMI-mediated cardiovascular lever, citing a near six-fold OSAS risk increment for every 10% BMI rise.

Additional corpus sources included animal/preclinical evidence; within-corpus tensions in the cardiometabolic class are dense and must be read carefully. A second layer of conflict emerges between Rivera 2024's positive effect and the null directions reported by Randomisation to Endobarrier Alone 2017, Zhang 2024, Ghanim 2024, Mullur 2024, Alshehri 2025, Noordam 2025, Fang 2026, Bethel 2021, and Baviera 2022. A parallel layer separates the direct randomized evidence in Impact of GLP Receptor 2026 from the indirect observational and review evidence across the remaining source set, including Xu 2022, Piccini 2023, Coleman 2025, and PCOS 2022, an indirectness gap that should be preserved when integrating the cardiometabolic evidence base rather than collapsed across directness strata. (Detailed study-by-study endpoint values, including all p-values, are tabulated in the evidence synthesis.)

### Contextual Adjacent Evidence Outcomes


The contextual outcome class is the dominant stratum in the curated GLP-1 corpus, comprising 16 heterogeneous studies ranging from large CVOT meta-analyses to mechanistic reviews and a single case report.

Quantitative cerebrovascular and cardiorenal effects diverge by endpoint and by active comparator.

Mechanistically, the contextual evidence base draws on three distinct substrate types. In a clinical RCT layer, Alkhatimalla-style pharmacokinetic characterization describes semaglutide as 94% structurally similar to endogenous GLP-1, with a half-life of 155–184 hours achieved by reduced metabolic clearance, and follow-up windows extending to 208 weeks in cited cohorts.

Within-corpus tensions concentrate around Wu 2022, which is the only source tagged with a negative effect direction in this outcome class.

The disagreement is most interpretable as endpoint-specific: Wu 2022 interrogates arrhythmia signals, whereas the conflicting null sources report on renal composites, behavioral outcomes, and stroke subtypes, each of which has a distinct biological substrate.

### Dosing and Pharmacokinetics Outcomes


The single included source addressing dosing and pharmacokinetics, Schneck 2024, is a population pharmacokinetic analysis of tirzepatide, a GIP/GLP receptor agonist administered subcutaneously in adults. The endpoint characterization centers on terminal half-life, exposure–response, and the once-weekly dosing schedule that follows the 4-week titration step. The canonical anchor for clinical dosing, as documented in the source, specifies that after 4 weeks the dose can be increased to 5 mg s.c. q.w., a transition that supports the sustained-exposure profile required for chronic administration. The study design is observational rather than interventional, and duration is framed by the population PK sampling strategy rather than a fixed follow-up window.

Quantitative findings in Schneck 2024 converge on a half-life of approximately 5 days, a value that underwrites the once-weekly dosing interval. The source reports P < 0.01 and P < 0.001 as the model-derived significance markers supporting the exposure–response characterization, which jointly validate the sustained plasma profile observed across the dosing interval. These model-anchored results are reported without rounding or transformation in this synthesis. Because the source carries no clinical endpoint beyond PK modeling, the outcome class resolves entirely on pharmacokinetic rather than efficacy metrics.

Mechanistically, the long half-life and once-weekly exposure profile in Schneck 2024 are relevant to longevity-class outcomes because sustained GLP receptor engagement is the upstream substrate for downstream cardiometabolic and body-composition effects tracked in adjacent outcome classes. The indirectness flag on the source is therefore a within-corpus signal that PK modeling is upstream of, not coextensive with, longevity endpoints.

Within-corpus tensions on dosing and pharmacokinetics are limited to a single source, so no pairwise disagreements can be surfaced for this outcome class. By contrast, the broader corpus places cardiometabolic, body composition, and glycemic outcomes downstream of the PK envelope that Schneck 2024 establishes, and the indirectness flag functions as the integration point rather than as a contradiction. The PK finding of sustained exposure therefore reads as a permissive upstream condition rather than as direct longevity evidence, consistent with the integrating thesis that mechanistic plausibility coexists with mixed or sparse human-RCT evidence.

### Immune and Inflammation Outcomes


The corpus contains a single observational cohort study, Zietek 2016, that directly frames inflammation as a convergence point between metabolic disease and enteroendocrine biology. The study population is described as adults, and the design is observational rather than interventional, which constrains causal inference about GLP-1 signaling on inflammatory endpoints. The cited thesis foregrounds enteroendocrine cells (EEC) as a numerically sparse but hormonally rich compartment, noting they comprise approximately only 1% of the epithelium yet secrete more than 20 different peptide hormones. This anatomical and quantitative baseline establishes the cellular substrate from which downstream immune and metabolic effects of GLP-1 are hypothesized to propagate. No effect direction is recorded for inflammatory endpoints in the source, consistent with a null designation at the level of direct measurement.

Quantitatively, Zietek 2016 contributes no p-values within the source set, and no effect direction is annotated for any inflammatory endpoint. The lack of a recorded p-value and the null effect-direction flag indicate that this study does not provide a measurable numeric signal for immune or inflammatory outcomes within the curated evidence base. Readers seeking an effect size or statistical estimate for inflammation-related GLP-1 effects in this study will find none, and the source itself does not support a quantitative claim beyond the anatomical and hormonal composition figures cited above. The absence of reported p-values is itself informative: it suggests the inflammatory framing in this source is mechanistic and contextual rather than inferential.

Preclinical and translational work not in this source consistently links enteroendocrine hormone release to innate immune cell activity, but within the curated corpus only the observational Zietek 2016 study is available to anchor the inflammation-related narrative. Consequently, the mechanistic substrate for an inflammation-mediated GLP-1 longevity pathway is presently supported by indirect, anatomical reasoning rather than by direct clinical RCT evidence in this corpus.

Within the curated corpus, no same-outcome tension pairs were registered for the immune inflammation class, so the only available discussion of disagreement concerns cross-class contrasts. By contrast, the picking thesis notes that positive signals for GLP-1 appear in longevity and mortality survival outcome classes, while null findings dominate cardiometabolic and contextual other domains; the immune inflammation class itself sits at the mechanistic, indirect end of this distribution. No conflicts between immune inflammation and other outcome classes are surfaced in the cross-study disagreement map, which keeps the discussion internally consistent for this subsection.

### Longevity Outcomes


Seven curated evidence streams converge on the longevity outcome class, spanning systematic reviews with meta-analyses, real-world observational cohorts, and population-based registry studies. Kelkar 2024 extended the analysis to overweight or obese non-diabetic adults, providing a complementary population in which the cardiorenal signal can be evaluated independently of a diabetes diagnosis. Together these reviews define the analytic frame within which single-cohort evidence (Sorensen 2025; Karacabeyli 2024; Li 2026) and racial-subgroup analyses (Kang 2018) are interpreted.

The quantitative signal is strongest and most concordant in the systematic-review tier. Giugliano 2021 reported the headline 14% relative MACE reduction (P = 0.006) alongside additional component-level findings (all-cause mortality P = 0.127; CV mortality P = 0.016; stroke P = 0.007; MI P = 0.023; all-cause hospitalisation P = 0.012; the composite of all-cause death or hospitalisation for heart failure P < 0.001; and a non-significant renal composite P = 0.08).

Mechanistically, the longevity signal is anchored in cardiorenal protection rather than direct geroprotection. The clinical RCTs and meta-analyses (Giugliano 2021; Kelkar 2024; Stefanou 2024b) demonstrate reductions in atherosclerotic and heart-failure endpoints that translate into survival advantage only indirectly. Preclinical and translational substrates — such as attenuation of vascular inflammation, natriuresis, and weight-dependent metabolic unloading — are consistent with the observed clinical magnitudes, but no enrolled clinical population in the curated corpus was designed to test a primary longevity endpoint, leaving the mechanistic substrate as the principal explanatory scaffold.

### Mortality and Survival Outcomes


Within the curated evidence base, two sources address the mortality survival outcome class and together frame an unresolved but methodologically informative question. By contrast with the pooled trial synthesis, the Danish registry study reports a null direction on mortality after adjustment, illustrating that the same drug class can yield divergent headline signals depending on whether evidence is drawn from randomized trials or real-world new-user active-comparator cohorts.

The contrast is most visible in the cardiovascular and mortality headline estimates, where the strongest signals (P < 0.01) co-exist with borderline-null secondary outcomes (P = 0.06, P = 0.0795), a pattern consistent with heterogeneity across the underlying trial populations. the evidence synthesis carries the full study-by-study p-value grid; readers should consult it for the per-comparison numerics rather than relying on the narrative summary alone.

The mechanistic substrate underlying this functional finding is the well-described GLP-1 receptor distribution on pancreatic islet, cardiovascular, and central nervous system tissue, but the divergence between the meta-analytic mortality signal and the registry-level null observation is more plausibly attributable to differences in design, active comparator, and unmeasured confounding than to biology alone.

Mechanistically, the meta-analysis pools placebo-controlled cardiovascular outcome trials in which the comparator itself is associated with elevated event rates, whereas the Danish cohort uses active-comparator new-user groups (SGLT2i, DPP-4i) that themselves have cardioprotective signal, plausibly narrowing the detectable margin. The clinical RCT direction is therefore positive on mortality, while the mechanistic human observational evidence, in this corpus, is null; this is a substantive disagreement on the magnitude of population-level benefit, not a contradiction on the presence of any effect, and it should be reported as such in any longevity-oriented synthesis.

### Muscle Function Outcomes


The two curated references converging on the muscle function outcome class address the skeletal and muscular sequelae of GLP-1 receptor agonist exposure rather than contractile performance per se, and both frame their endpoints around bone turnover balance and bone strength in populations at elevated fracture risk. No p-values or effect-size estimates are recorded in the source, and the effect direction is logged as unclear pending the trial readout.

The second muscle function anchor, Effect of Semaglutide on Bone 2022, is a systematic review or meta-analysis examining the effect of semaglutide on bone turnover in patients with increased risk of bone fracture, with the source excerpt noting coverage of an adult population up to approximately 85 years of age; as a review-level contribution it is logged with directness = review and effect direction = unclear, and no p-values are recorded in the source. The relevant quantitative anchors that ARE present in the sources are the trial-class label (RCT vs systematic review) and the population descriptor, so any numeric statement in this subsection is restricted to those register values rather than computed or extrapolated estimates.

Mechanistically, the muscle function class is being interrogated because GLP-1 receptor signaling interfaces with the anabolic-catabolic balance of skeletal tissue and, by extension, the neuromuscular substrate that supports functional endpoints; the source-level summary of Effect of Oral Semaglutide 2026 frames the trial hypothesis as a balance question between bone build-up and degradation, which is the canonical clinical-RCT operationalization of that mechanistic substrate. Because the effect direction in both sources is logged as unclear, the mechanistic plausibility argument is not yet anchored to a confirmed human in vivo signal in the curated corpus — the mechanistic expectation stands while the direct RCT and the review-level synthesis both report the question rather than a resolved answer.

The within-corpus tension on muscle function is a directness-of-evidence gap rather than a directional disagreement: Effect of Oral Semaglutide 2026 is a direct clinical RCT (severity-3 pairing per the cross-study disagreement map, coded indirectness gap between muscle function and the two sources) while Effect of Semaglutide on Bone 2022 is a review-level synthesis, and standard academic practice treats these as complementary rather than contradictory — the RCT supplies the primary functional signal and the systematic review situates that signal against prior literature. Because both sources log effect direction as unclear, no quantitative claim of benefit or harm can be made; the appropriate synthesis statement is that the corpus contains one direct RCT and one review on muscle function, both with unresolved direction, and the question of whether oral or injectable semaglutide shifts the bone build-up/degradation balance in fracture-risk populations remains open in the curated evidence base.

### Safety and Comorbidity Outcomes


The safety-comorbidity evidence base is dominated by observational cohorts and post-marketing pharmacovigilance rather than dedicated long-duration RCTs. Shah 2026 functions as a clinician counseling guide for adults considering therapy, framing safety concerns in practical terms. Baar 2019 reviews the incretin pathway in diabetic kidney disease and explicitly identifies a 5-year semaglutide trial in patients with albuminuria and declined eGFR, with a primary endpoint of persistent eGFR decline.

Quantitative findings across the four safety-comorbidity sources do not converge on a single direction. the evidence synthesis (Per-Study Endpoint Evidence) carries each study × p-value tuple in detail; the prose here deliberately references rather than restates them.

Mechanistically, the safety-comorbidity substrate overlaps with the cardiometabolic and renal pathways that the broader corpus treats as plausible mediators of longevity effects. The clinical RCT evidence in Ahmed 2025 (MACE endpoints) and the mechanistic human studies in Baar 2019 (renal hemodynamic and albuminuria pathways) both probe how GLP-1 receptor agonism interfaces with established end-organ disease. By contrast, Yang 2022 and Shah 2026 represent real-world pharmacovigilance and clinician-facing synthesis rather than dedicated mechanistic work, so any inferred mechanism linking their tumor or pancreatitis observations to longevity-relevant biology should be treated as hypothesis-generating only.

Within-corpus tensions in this outcome class surface between the cardiovascular-comparison framing of Ahmed 2025 and the tumor-adverse-event framing of Yang 2022. The disagreement is not so much a contradiction as an evidence-base asymmetry: cardiovascular MACE has RCT-pooled data, tumor signals have FAERS-level observational data, and renal outcomes remain in trial follow-up.

### Deficiency Prevalence Outcomes


No p-values are listed in the source, and the thesis is registered as null with respect to deficiency prevalence, indicating that within the supplied excerpts the comparative safety signal did not separate the two drug classes in a uniform direction across frailty strata (Kutz 2021).

The source does not record a numerical p-value for either estimate, and the effect direction is tagged as null in the curated record, so the synthesis treats the reported hazard ratios as descriptive point estimates within a sequential monitoring framework rather than as confirmatory tests of a deficiency-prevalence hypothesis (Kutz 2021).

Within-corpus tensions specific to this outcome class are limited because only a single source (Kutz 2021) maps onto deficiency prevalence, and the cross-study disagreement map records no same-outcome non-orthogonal pairs for this class. The boundary of interpretability is therefore narrow: the source characterizes a sequential safety comparison in older adults stratified by frailty, with hazard ratios for diabetic ketoacidosis that varied in magnitude across analyses and frailty strata, and the synthesis cannot resolve a direction-of-effect dispute because no second source contests the estimate (Kutz 2021). For the broader GLP-1 thesis, the implication is qualitative rather than quantitative: the source underscores that any claim of anti-aging benefit in older adults must be evaluated against the safety monitoring context provided by Kutz 2021, with the precise upper confidence bound of the broader estimate remaining unspecified in the available record.

Deficiency Prevalence remains a separate Results slice (n=1; claims=7; no extracted directional signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

## Cross-Domain Synthesis

The first and most load-bearing cross-domain tension is between the longevity-class evidence of cardiovascular and all-cause mortality benefit and the cardiometabolic-class evidence in which Zakaria 2024 reports a negative direction in the same patient population. The boundary condition is therefore protocolized, adherent use versus real-world uptake; the resolving evidence would be a propensity-matched effectiveness study stratified by adherence and dose-titration status. Until that adjudication is available, the longevity and cardiometabolic signals can be interpreted as complementary rather than contradictory: the longevity estimates quantify efficacy under trial conditions, while Zakaria 2024's negative direction quantifies effectiveness under routine-care conditions, an indirectness gap that the synthesis must keep separate.

Another cross-domain tension is the disagreement pair between Kang 2018 and Kelkar 2024 on the longevity outcome class itself. Kelkar 2024 by contrast pools predominantly Western non-diabetic populations, which differ in both baseline risk and the magnitude of weight-loss-induced cardiometabolic change. The boundary condition is ancestry and baseline risk: long-acting GLP-1RA benefit on longevity endpoints may be attenuated or absent in lower-BMI Asian populations in whom weight-loss-derived MACE reduction is smaller. The resolving evidence would be ancestry-stratified individual-patient meta-analysis with prespecified cardiovascular-risk subgroup definitions, which the existing reviews do not provide. The synthesis must therefore not present a single 'longevity benefit' estimate when the underlying trial populations disagree on direction by ancestry, and must hold Kang 2018 and Kelkar 2024 as competing findings pending that adjudication.

A third load-bearing cross-domain tension is the indirectness gap between the two direct RCTs in the corpus and the large body of indirect observational and review-level evidence. Impact of GLP Receptor 2026 (RCT, cardiometabolic) reports MACE reductions of 26% in SUSTAIN-6 and 20% in SELECT for semaglutide, and Effect of Oral Semaglutide 2026 (RCT, muscle function) directly measures bone turnover. The mechanism-level concern is confounding by indication in routine-care cohorts, where sicker patients are channelled to GLP-1RAs and healthier patients to alternative classes, generating differential baseline cardiovascular risk that cannot be fully removed by covariate adjustment. Piccini 2023 itself notes that BMI and HbA1c change did not explain the observed effect. The boundary condition is directness of inference: RCT-derived hazard ratios quantify drug effect under controlled exposure, whereas observational hazard ratios quantify drug effect plus channeling bias plus adherence. The resolving evidence would be pre-registered target-trial emulation with active-comparator new-user design. The synthesis must therefore treat the direct RCT signals (Impact of GLP Receptor 2026, Effect of Oral Semaglutide 2026) as the primary inferential substrate and the observational signals as supportive but not confirmatory for hard outcomes.

Another cross-domain tension, central to the anti-aging framing of GLP-1, is the surrogate-endpoint vs hard-outcome gap. The brief positions longevity and mortality survival as the positive-signal classes, yet the corpus also contains documented surrogates (HbA1c reduction, weight loss, blood-pressure reduction) that have not consistently translated to hard-outcome gains. The boundary condition is the disconnect between weight loss and event reduction: rapid pharmacologic weight loss in GLP-1RA-treated patients is robustly demonstrable, but the MACE benefit reported in longevity-class meta-analyses cannot be explained away by weight loss alone. The synthesis must therefore avoid the slide from 'GLP-1RAs produce large weight loss' to 'GLP-1RAs extend human lifespan' and must hedge the longevity claim as a hard-outcome signal whose mediator chain is incomplete, not a fully mechanistically traced effect.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

Cross-domain interpretation compares outcome classes and identifies where signals converge or diverge. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation
separates direct clinical findings from mechanistic and adjacent evidence,
preserving uncertainty where endpoint, population, comparator, or follow-up
differs. This conservative boundary keeps the scientific question visible
without inserting unsupported numeric detail or stronger causal language than
the retained evidence allows. Where studies point in different directions,
the synthesis treats that disagreement as information about design and
applicability rather than as noise. The key question becomes which population,
intervention schedule, comparator, and endpoint layer would be required for the
claim to survive a prospective test. This preserves the practical implication
for readers: favorable signals can justify targeted follow-up, while unresolved
tradeoffs still limit broad clinical or public-health recommendations.



### Load-Bearing Tensions

Each tension below is load-bearing: it changes whether the outcome is read as a robust class effect or as design-contingent evidence. Numeric anchors remain in the structured evidence tables rather than in this interpretive list.

- Rivera 2024 versus Zakaria 2024: a Cardiometabolic disagreement tension. Leading explanations: Dose-regime difference: intermittent vs chronic dosing produces qualitatively different effects; Co-intervention interaction: a concurrent intervention (e. For example, exercise) modifies the drug effect.
- Kelkar 2024 versus Kang 2018: a Longevity disagreement tension. Leading explanations: Dose-regime difference: intermittent vs chronic dosing produces qualitatively different effects; Co-intervention interaction: a concurrent intervention (e. For example, exercise) modifies the drug effect.
- Lucero 2023 versus Wu 2022: a Contextual Adjacent Evidence null vs negative tension. Leading explanations: Effect is endpoint-distance dependent: signed at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity.
- Stefanou 2024 versus Hastrup 2026: a Mortality and Survival null vs positive tension. Leading explanations: Effect is endpoint-distance dependent: positive at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity.
- Li 2026 versus Giugliano 2021: a Longevity null vs positive tension. Leading explanations: Effect is endpoint-distance dependent: positive at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity.
## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 52 curated reference papers, the evidence base for Glp 1 shows a context-dependent profile. Positive signals appear in: longevity, mortality survival. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 52 included sources. The evidence-tier distribution is: B2 (n=39), B1 (n=11), A1 (n=2). The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: type 2 diabetes patients; older adults; adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.


The corpus does not contain a long-term mortality or hard-longevity randomized trial in non-diabetic adults, which is the population in which an anti-aging claim would have the largest external-validity footprint. Because no trial in the corpus randomized healthy or non-diabetic adults to a GLP-1 receptor agonist with a primary longevity endpoint, the headline conclusion that the GLP-1 case is 'incomplete' cannot be tempered or confirmed by direct human evidence in the target population.

Several clinically salient outcomes are touched by only a single source, so the corpus cannot internally replicate the signal.

Endpoint scope is narrower than the longevity framing implies. None of the curated trials or cohorts reports a primary endpoint of healthspan, disability-free survival, frailty incidence, cognitive decline, or longevity as operationalized by a hard endpoint such as survival to a defined age. Because of this, the gap between the surrogate endpoint the corpus measures and the longevity endpoint it claims to inform cannot be closed by any source in the file, a caution that generalizes from Ioannidis 2005 on surrogate-to-hard-outcome inference.

A mechanism-to-clinic gap also constrains the bone, muscle, and frailty channels that an anti-aging argument would need. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. Pending further trials, the intervention should not be used off-label for geroprotection or anti-aging purposes outside clinical-trial settings given current evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

## What This Synthesis Adds

This synthesis maps 52 included sources on GLP-1 Longevity across 9 outcome classes and 136 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 52 curated reference papers, the evidence base for Glp 1 shows a context-dependent profile. Positive signals appear in: longevity, mortality survival. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the disagreement between Rivera 2024 and Zakaria 2024 on cardiometabolic (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Khawaji 2025, Stefanou 2024, Giugliano 2021, Giugliano 2022, Chikatimalla 2026) emphasize convergent signals on GLP-1 Longevity. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 7 | negative, null, positive, unclear | conflict-resolution gap |
| cardiometabolic | 1 | 17 | mixed, negative, null, positive, unclear | conflict-resolution gap |
| muscle function | 1 | 1 | unclear | replication gap |
| contextual adjacent evidence | 0 | 16 | mixed, negative, null, unclear | conflict-resolution gap |
| mortality and survival | 0 | 2 | null, positive | conflict-resolution gap |
| deficiency prevalence | 0 | 1 | null | direct interventional hard-endpoint gap |
| dosing and pharmacokinetics | 0 | 1 | null | direct interventional hard-endpoint gap |
| immune and inflammation | 0 | 1 | null | direct interventional hard-endpoint gap |
| safety and comorbidity | 0 | 4 | mixed, null | direct interventional hard-endpoint gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: conflict-resolution gap | 0 direct and 7 indirect sources; direction profile: negative, null, positive, unclear |
| P2 | cardiometabolic: conflict-resolution gap | 1 direct and 17 indirect sources; direction profile: mixed, negative, null, positive, unclear |
| P3 | muscle function: replication gap | 1 direct and 1 indirect sources; direction profile: unclear |
| P4 | contextual adjacent evidence: conflict-resolution gap | 0 direct and 16 indirect sources; direction profile: mixed, negative, null, unclear |
| P5 | mortality and survival: conflict-resolution gap | 0 direct and 2 indirect sources; direction profile: null, positive |

### Next-Study Design Recommendation

The next high-yield study for GLP-1 Longevity should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Impact of GLP Receptor 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Effect of Oral Semaglutide 2026; tier=A1; directness=direct; endpoint=muscle function; direction=unclear.
- Khawaji 2025; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.001.
- Stefanou 2024; tier=B1; directness=review; endpoint=mortality survival; direction=positive; representative statistic=P < 0.01.
- Giugliano 2021; tier=B1; directness=review; endpoint=longevity; direction=positive; representative statistic=P < 0.001.
- Giugliano 2022; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.059.
- Chikatimalla 2026; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.017.
- Kelkar 2024; tier=B1; directness=review; endpoint=longevity; direction=positive; representative statistic=P < 0.0001.
- Stefanou 2024b; tier=B1; directness=review; endpoint=longevity; direction=unclear.
- Rivera 2024; tier=B1; directness=review; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Impact of GLP-1 Receptor Agonists and Dual/Triple Incretin Therapies on Cardiometabolic Outcomes Beyond Glycemic Control: Evidence from Recent Randomized Trials: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=5.
- The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial: outcome=muscle function; directness=direct; tier=A1; direction=unclear; claims=1.
- Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=mixed; claims=201.
- Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis: outcome=mortality survival; directness=review; tier=B1; direction=positive; claims=86.
- GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs: outcome=longevity; directness=review; tier=B1; direction=positive; claims=61.
- The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=55.
- GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=31.
- Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis: outcome=longevity; directness=review; tier=B1; direction=positive; claims=22.
- Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=9.
- Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=8.
- Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity): outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=3.
- The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture: outcome=muscle function; directness=review; tier=B1; direction=unclear; claims=1.
- GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS): outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=1.
- Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=141.
- Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=102.
- Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study: outcome=cardiometabolic; directness=indirect; tier=B2; direction=negative; claims=99.
- Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=negative; claims=59.
- SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials: outcome=safety comorbidity; directness=review; tier=B2; direction=mixed; claims=51.
- Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=50.
- Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=50.
- Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=50.
- Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=44.
- Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=44.
- The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=38.
- HbA 1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=37.
- Real-World Use of GLP-1 Receptor Agonist Liraglutide in Adolescents with Obesity: A First Longitudinal Single-Center Analysis from Switzerland †: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=36.
- The multifaceted effects of semaglutide: exploring its broad therapeutic applications: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=32.
- GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS: outcome=safety comorbidity; directness=indirect; tier=B2; direction=null; claims=31.
- Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=28.
- Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=21.
- 12608 Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With Glp-1 Receptor Agonist Treatment: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=19.
- Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials: outcome=longevity; directness=review; tier=B2; direction=negative; claims=19.
- Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=18.
- Cost-effectiveness of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=18.
- GLP-1 receptor agonist–induced diabetic ketoacidosis: A case report: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=18.
- MON-701 A case which GLP 1 receptor agonist semaglutide enabled the management of both obesity and diabetes mellitus, suggesting the potential for diabetes remission: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=15.
- GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=14.
- Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=14.
- Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=null; claims=7.
- A Nationwide Danish Comparative Effectiveness Study of GLP‐1 RA, SGLT2i and DPP‐4i Treatment on Risk of Stroke, Myocardial Infarction and Mortality in Type 2 Diabetes: outcome=mortality survival; directness=indirect; tier=B2; direction=null; claims=6.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 5 disagreement: Rivera 2024 vs Zakaria 2024; Rivera 2024 reports positive effect on cardiometabolic; Zakaria 2024 reports negative on the same outcome — direct conflict
- Severity 5 disagreement: Kelkar 2024 vs Kang 2018; Kelkar 2024 reports positive effect on longevity; Kang 2018 reports negative on the same outcome — direct conflict
- Severity 5 disagreement: Kang 2018 vs Giugliano 2021; Kang 2018 reports negative effect on longevity; Giugliano 2021 reports positive on the same outcome — direct conflict
- Severity 4 null vs negative: Randomisation to Endobarrier Alone 2017 vs Zakaria 2024; Zakaria 2024 (negative on cardiometabolic) vs Randomisation to Endobarrier Alone 2017 (null on cardiometabolic) — partial conflict
- Severity 4 null vs negative: Lucero 2023 vs Wu 2022; Wu 2022 (negative on contextual other) vs Lucero 2023 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Brockmeyer 2024 vs Wu 2022; Wu 2022 (negative on contextual other) vs Brockmeyer 2024 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Zakaria 2024 vs Zhang 2024; Zakaria 2024 (negative on cardiometabolic) vs Zhang 2024 (null on cardiometabolic) — partial conflict
- Severity 4 null vs negative: Zakaria 2024 vs Ghanim 2024; Zakaria 2024 (negative on cardiometabolic) vs Ghanim 2024 (null on cardiometabolic) — partial conflict

## Conclusion

For GLP-1 longevity, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. Pending further trials, the intervention should not be used off-label for geroprotection or anti-aging purposes outside clinical-trial settings given current evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.



Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Wei 2022, Wang 2024, McNally 2026, Melo 2021, Landau 2025, Baldera-Rodriguez 2026, Khan 2026, Paceana 2026, Schernthaner 2020.
## References

- **Khawaji 2025.** _Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration._ Journal of Obesity, 2025. DOI: 10.1155/jobe/3442754. PMID: 40746703.
- **Piccini 2023.** _Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study._ Cardiovascular Diabetology, 2023. DOI: 10.1186/s12933-023-01800-z. PMID: 36966321.
- **Sorensen 2025.** _Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes._ Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-02915-1. PMID: 41053738.
- **Zakaria 2024.** _Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study._ Metabolism Open, 2024. DOI: 10.1016/j.metop.2024.100283. PMID: 38699398.
- **Stefanou 2024.** _Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis._ Therapeutic Advances in Neurological Disorders, 2024. DOI: 10.1177/17562864241281903. PMID: 39345822.
- **Giugliano 2021.** _GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs._ Cardiovascular Diabetology, 2021. DOI: 10.1186/s12933-021-01366-8. PMID: 34526024.
- **Wu 2022.** _Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials._ Diabetology & Metabolic Syndrome, 2022. DOI: 10.1186/s13098-022-00970-2. PMID: 36572913.
- **Giugliano 2022.** _The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs._ Cardiovascular Diabetology, 2022. DOI: 10.1186/s12933-022-01474-z. PMID: 35296336.
- **Ahmed 2025.** _SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials._ BMC Cardiovascular Disorders, 2025. DOI: 10.1186/s12872-025-05455-4. PMID: 41454299.
- **Brockmeyer 2024.** _Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data._ Journal of Nephrology, 2024. DOI: 10.1007/s40620-023-01858-8. PMID: 38236473.
- **Coleman 2025.** _Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis._ Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-02866-7. PMID: 40849664.
- **Xu 2022.** _Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations._ Cardiovascular Therapeutics, 2022. DOI: 10.1155/2022/6820377. PMID: 36474714.
- **Schneck 2024.** _Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide._ CPT: Pharmacometrics & Systems Pharmacology, 2024. DOI: 10.1002/psp4.13099. PMID: 38356317.
- **Baviera 2022.** _Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study._ Cardiovascular Diabetology, 2022. DOI: 10.1186/s12933-022-01572-y. PMID: 35999556.
- **Lucero 2023.** _The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis._ JMIR Medical Education, 2023. DOI: 10.2196/48586. PMID: 37642994.
- **Bethel 2021.** _HbA 1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression._ Diabetes Care, 2021. DOI: 10.2337/dc20-1815. PMID: 33444163.
- **Noordam 2025.** _Real-World Use of GLP-1 Receptor Agonist Liraglutide in Adolescents with Obesity: A First Longitudinal Single-Center Analysis from Switzerland †._ Children, 2025. DOI: 10.3390/children12121716. PMID: 41462856.
- **Alkhatib 2025.** _The multifaceted effects of semaglutide: exploring its broad therapeutic applications._ Future Science OA, 2025. DOI: 10.1080/20565623.2025.2483607. PMID: 40904035.
- **Chikatimalla 2026.** _GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers._ Annals of Medicine, 2026. DOI: 10.1080/07853890.2026.2660386. PMID: 41999297.
- **Yang 2022.** _GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS._ Frontiers in Pharmacology, 2022. DOI: 10.3389/fphar.2022.925377. PMID: 36386208.
- **Wei 2022.** _Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis._ Frontiers in Endocrinology, 2022. DOI: 10.3389/fendo.2022.1007980. PMID: 36545339.
- **Kelkar 2024.** _Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis._ Frontiers in Cardiovascular Medicine, 2024. DOI: 10.3389/fcvm.2024.1453297. PMID: 39323759.
- **Wang 2024.** _Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study._ Molecular Psychiatry, 2024. DOI: 10.1038/s41380-024-02498-5. PMID: 38486046.
- **Ghanim 2024.** _12608 Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With Glp-1 Receptor Agonist Treatment._ Journal of the Endocrine Society, 2024. DOI: 10.1210/jendso/bvae163.019.
- **Kang 2018.** _Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials._ Diabetes & Metabolism Journal, 2018. DOI: 10.4093/dmj.2018.0070. PMID: 30604598.
- **Karacabeyli 2024.** _Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study._ PLOS ONE, 2024. DOI: 10.1371/journal.pone.0308533. PMID: 39116084.
- **Zhang 2024.** _GLP-1 receptor agonist–induced diabetic ketoacidosis: A case report._ Medicine, 2024. DOI: 10.1097/MD.0000000000039799. PMID: 39331877.
- **McNally 2026.** _Cost-effectiveness of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada._ CMAJ : Canadian Medical Association Journal, 2026. DOI: 10.1503/cmaj.250591. PMID: 41730540.
- **Hashimoto 2025.** _MON-701 A case which GLP 1 receptor agonist semaglutide enabled the management of both obesity and diabetes mellitus, suggesting the potential for diabetes remission._ Journal of the Endocrine Society, 2025. DOI: 10.1210/jendso/bvaf149.039.
- **Crowley 2024.** _GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report._ Frontiers in Oncology, 2024. DOI: 10.3389/fonc.2024.1392375. PMID: 38699640.
- **Melo 2021.** _Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?._ Diabetology & Metabolic Syndrome, 2021. DOI: 10.1186/s13098-021-00698-5. PMID: 34315528.
- **Stefanou 2024b.** _Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis._ Eur Stroke J, 2024. DOI: 10.1177/23969873241234238. PMID: 38400569.
- **Rivera 2024.** _Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression._ medRxiv preprint, 2024. DOI: 10.1101/2024.01.29.24301971.
- **Kutz 2021.** _Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.803.
- **Hastrup 2026.** _A Nationwide Danish Comparative Effectiveness Study of GLP‐1 RA, SGLT2i and DPP‐4i Treatment on Risk of Stroke, Myocardial Infarction and Mortality in Type 2 Diabetes._ Endocrinology, Diabetes & Metabolism, 2026. DOI: 10.1002/edm2.70165. PMID: 41578841.
- **Impact of GLP Receptor 2026.** _Impact of GLP-1 Receptor Agonists and Dual/Triple Incretin Therapies on Cardiometabolic Outcomes Beyond Glycemic Control: Evidence from Recent Randomized Trials._ Journal of Diabetes Research Review & Reports, 2026. DOI: 10.47363/jdrr/2026(8)211.
- **Landau 2025.** _Employing an Artificial Intelligence Platform to Enhance Treatment Responses to GLP-1 Agonists by Utilizing Metabolic Variability Signatures Based on the Constrained Disorder Principle._ Biomedicines, 2025. DOI: 10.3390/biomedicines13112645. PMID: 41301738.
- **Baldera-Rodriguez 2026.** _Unmasking an insulinoma: recurrent Hypoglycemia in a young patient following GLP-1 receptor agonist therapy —A case report._ Oxford Medical Case Reports, 2026. DOI: 10.1093/omcr/omaf283. PMID: 41589102.
- **Khan 2026.** _Integrating GLP-1 Receptor Agonists into Modern Stroke Prevention: Evidence, Mechanisms, and Clinical Consideration—A Narrative Review._ Biomedicines, 2026. DOI: 10.3390/biomedicines14040743. PMID: 42072284.
- **Randomisation to Endobarrier Alone 2017.** _Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)._ 2017. Identifier unavailable; no DOI or PMID in source metadata.
- **Alshehri 2025.** _New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov._ Medicine, 2025. DOI: 10.1097/MD.0000000000044917. PMID: 41054173.
- **Shah 2026.** _Addressing patient concerns about the ‘newness’ and long-term safety of GLP-1 receptor agonists: A clinician’s guide to counseling._ American Journal of Preventive Cardiology, 2026. DOI: 10.1016/j.ajpc.2026.101418. PMID: 41608676.
- **Li 2026.** _Potential application of mono-, dual-, and triple-target GLP-1 receptor agonists in improving the prognosis of patients with diabetic foot ulcers._ Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2025.1754925. PMID: 41647111.
- **Fang 2026.** _GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives._ Frontiers in Medicine, 2026. DOI: 10.3389/fmed.2026.1752341. PMID: 42136855.
- **Paceana 2026.** _Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists._ Pharmaceutics, 2026. DOI: 10.3390/pharmaceutics18050620. PMID: 42198313.
- **Baar 2019.** _The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists._ Therapeutic Advances in Endocrinology and Metabolism, 2019. DOI: 10.1177/2042018819865398. PMID: 31384419.
- **Schernthaner 2020.** _Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes._ Cardiovascular Diabetology, 2020. DOI: 10.1186/s12933-020-01154-w. PMID: 33097060.
- **PCOS 2022.** _GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)._ 2022. Identifier unavailable; no DOI or PMID in source metadata.
- **Effect of Oral Semaglutide 2026.** _The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial._ 2026. Identifier unavailable; no DOI or PMID in source metadata.
- **Effect of Semaglutide on Bone 2022.** _The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture._ 2022. Identifier unavailable; no DOI or PMID in source metadata.
- **Mullur 2024.** _GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms._ The Journal of Endocrinology, 2024. DOI: 10.1530/JOE-24-0046. PMID: 39145614.
- **Zietek 2016.** _Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1._ Frontiers in Immunology, 2016. DOI: 10.3389/fimmu.2016.00154. PMID: 27148273.

### Background References

*Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*

- **Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923. PMID: 21205966.
- **WHO 2000.** _World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000._ PMID: 11234459.
- **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169. PMID: 30312372.
- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.

{
  "article_type": "evidence_map",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "55294f57-700e-484d-8893-908a24c86e60",
  "title": "Hypothesis-Generating Brief: GLP-1 longevity \u2014 full paper"
}